On Elexacaftor/Tezacaftor/Ivacaftor, Her Gut Symptoms Changed — Should Her Enzyme Dose?
A CFTR modulator that was never prescribed for her digestion has changed how she digests anyway — the question is whether her own improved symptoms are reliable enough evidence to actually lower a dose she's carried since infancy.
Ava M. is nineteen and just finished her first year at a college two states away from her family, the first extended stretch of time she's managed her own cystic fibrosis care without a parent double-checking her routine. She was diagnosed with pancreatic-insufficient CF in infancy and has taken weight-based pancreatic enzymes with every meal for as long as she can remember, dosing she and her family learned to calibrate carefully around higher-fat foods. Six months ago, she started elexacaftor/tezacaftor/ivacaftor, prescribed for its established lung-function benefit — not for her digestion, which nobody expected to change. It has changed anyway: she describes noticeably less bloating, more consistently formed stools, and says she's stopped needing the extra enzyme doses she used to take before pizza or a heavier restaurant meal.
That pattern is real but genuinely partial in the literature — Sankararaman and colleagues' 2025 pediatric cohort study found a real fecal-elastase response to elexacaftor/tezacaftor/ivacaftor in about a fifth of previously pancreatic-insufficient patients, while several adult and older-pediatric cohorts found little to no average change, so CFTR modulators restoring some residual exocrine secretory capacity is real in a minority of pancreatic-insufficient patients rather than an expected effect, a genuine physiologic change layered on top of the drug's primary respiratory indication. Her fecal elastase, rechecked at this visit, has risen from severely low to moderately low — still abnormal, still consistent with insufficiency, but a real, measured shift in the same direction her symptoms describe. What her improved symptoms don't settle on their own is how much her actual fat absorption has changed, and whether a subjective sense of improvement is reliable enough to guide lowering a dose that has protected her growth and nutrition for nineteen years.
She came to this visit alone for the first time, having driven the four hours back from campus herself rather than have a parent make the trip with her, and mentioned that part of her interest in lowering her dose is genuinely practical: counting and carrying enzyme capsules for a full week between trips home has become its own logistical burden now that nobody is restocking her supply for her. Her dietitian noted that her meal patterns have shifted too since starting college — more dining-hall meals of inconsistent fat content, which makes her own report of needing fewer "extra doses" a harder signal to interpret cleanly than it would have been against her more predictable diet at home.
Clinic, six-month CFTR modulator follow-up
I'd trial a real reduction in her PERT dose. Her symptoms — less bloating, more formed stools, no longer needing extra doses for heavier meals — line up with a real pattern now described in observational cohorts of patients started on this modulator: genuine improved residual exocrine function, not just improved comfort. Her elastase moving from severely to moderately low is objective evidence in the same direction. Continuing her prior fixed dose indefinitely without testing that improvement risks over-dosing her for no reason.
Her symptom improvement is real, but it doesn't reliably tell us how much her actual fat absorption has changed — fecal elastase itself is an imperfect measure of clinically meaningful digestive capacity in CF, and a moderately-low result still means real insufficiency, not normalization. She's also nineteen and, for the first time, managing her own regimen alone at college — under-dosing during this transition, while she's still establishing her own routine, carries real nutritional risk that a purely symptom-guided taper could miss before it's caught.
I'm not arguing against ever adjusting her dose — the physiologic case for real change is genuine. I want that change guided by an objective measure, not her symptom report alone, especially given how much her daily supervision has just changed too.
Agreed: a modest, defined PERT dose reduction now, with a 72-hour fecal fat collection scheduled to objectively guide any further change rather than continuing on symptom report alone.
Not agreed: how quickly to move toward a larger reduction if the fecal fat collection confirms genuinely improved absorption. The gastroenterologist would move relatively quickly toward a substantially lower maintenance dose; the dietitian wants a slower, more incremental approach given how much is riding on her nutrition during her first year of unsupervised self-management.